Department of Surgery, Duke University Medical Center, Durham, NC, USA.
The Oregon Clinic, Portland, OR, USA.
Ann Surg Oncol. 2022 Sep;29(9):5422-5431. doi: 10.1245/s10434-022-12031-z. Epub 2022 Jun 20.
Optimal management of stage II/III gastric cancer requires multidisciplinary care, often necessitating treatment at more than one facility. We aimed to determine patterns of "fragmented" care and its impact on outcomes, including concordance with National Comprehensive Cancer Network (NCCN) guidelines and overall survival.
The 2006-2016 National Cancer Database was queried for patients with clinical stage II/III gastric adenocarcinoma who received preoperative therapy in addition to surgery. Patients were stratified based on whether surgery and chemotherapy/chemoradiation were performed at one versus multiple facilities (termed "coordinated" and "fragmented" care, respectively). Multivariable logistic regression was performed to identify factors associated with fragmented care. Survival was compared using Kaplan-Meier and Cox proportional hazards methods.
Overall, 2033 patients met study criteria: 1043 (51.3%) received coordinated care and 990 (48.7%) fragmented care. There was no significant difference in time to surgery or pathologic upstaging by care structure. On adjusted analysis, factors associated with receipt of fragmented care included increasing age and distance traveled to the treating facility. Factors associated with coordinated care included metropolitan residence and treatment at academic and high-volume centers. Fragmented care was associated with a reduction in guideline-preferred perioperative chemotherapy (odds ratio [OR] 0.78, 95% confidence interval [CI] 0.63-0.97, p = 0.02) and increased mortality (HR 1.16, 95% CI 1.00-1.34, p = 0.05).
For patients with stage II/III gastric cancer, fragmented care is associated with inferior outcomes, including a reduction in preferred perioperative treatment and survival. Further work is needed to ensure equitable outcomes among patients as complex cancer care becomes more regionalized.
Ⅱ/Ⅲ期胃癌的最佳治疗需要多学科的护理,通常需要在多个医疗机构进行治疗。我们旨在确定“碎片化”护理的模式及其对结果的影响,包括与国家综合癌症网络(NCCN)指南的一致性和总生存率。
2006 年至 2016 年,国家癌症数据库被查询用于接受术前治疗加手术的临床 II/III 期胃腺癌患者。根据手术和化疗/放化疗是否在一个或多个医疗机构进行,患者分层为“协调”和“碎片化”护理(分别称为“协调”和“碎片化”护理)。采用多变量逻辑回归确定与碎片化护理相关的因素。采用 Kaplan-Meier 和 Cox 比例风险方法比较生存情况。
总体而言,2033 例患者符合研究标准:1043 例(51.3%)接受协调护理,990 例(48.7%)接受碎片化护理。护理结构对手术时间或病理升级无显著影响。在调整分析中,接受碎片化护理的相关因素包括年龄增长和前往治疗机构的距离增加。接受协调护理的相关因素包括居住在大都市地区以及在学术和高容量中心接受治疗。碎片化护理与减少指南推荐的围手术期化疗相关(优势比 [OR] 0.78,95%置信区间 [CI] 0.63-0.97,p=0.02),并且死亡率增加(风险比 [HR] 1.16,95% CI 1.00-1.34,p=0.05)。
对于患有 II/III 期胃癌的患者,碎片化护理与较差的结果相关,包括减少首选围手术期治疗和生存。随着复杂癌症护理变得更加区域化,需要进一步努力确保患者获得公平的结果。